Steven J. Oosterling

3.8k total citations · 2 hit papers
42 papers, 1.3k citations indexed

About

Steven J. Oosterling is a scholar working on Oncology, Surgery and Immunology. According to data from OpenAlex, Steven J. Oosterling has authored 42 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 23 papers in Surgery and 7 papers in Immunology. Recurrent topics in Steven J. Oosterling's work include Colorectal Cancer Surgical Treatments (16 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Cancer, Stress, Anesthesia, and Immune Response (7 papers). Steven J. Oosterling is often cited by papers focused on Colorectal Cancer Surgical Treatments (16 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Cancer, Stress, Anesthesia, and Immune Response (7 papers). Steven J. Oosterling collaborates with scholars based in Netherlands, United States and Switzerland. Steven J. Oosterling's co-authors include Marjolein van Egmond, Gerben J. van der Bij, Robert H.J. Beelen, Sybren Meijer, Marijn Bögels, Joost R.M. van der Sijp, John Calvin Coffey, Hein B.A.C. Stockmann, Gerrit A. Meijer and R.H.J. Beelen and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Steven J. Oosterling

41 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study

2022 129 citations Myriam Chalabi, Y.L. Verschoor et al. Annals of Oncology profile →
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial

2024 40 citations Y.L. Verschoor, Sara Balduzzi et al. Nature Medicine profile →

Peers

Countries citing papers authored by Steven J. Oosterling

Since Specialization

Citations

This map shows the geographic impact of Steven J. Oosterling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven J. Oosterling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven J. Oosterling more than expected).

Fields of papers citing papers by Steven J. Oosterling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven J. Oosterling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven J. Oosterling. The network helps show where Steven J. Oosterling may publish in the future.

Co-authorship network of co-authors of Steven J. Oosterling

This figure shows the co-authorship network connecting the top 25 collaborators of Steven J. Oosterling. A scholar is included among the top collaborators of Steven J. Oosterling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven J. Oosterling. Steven J. Oosterling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial breakdown → 2024 ·Nature Medicine ·(unknown), Y.L. Verschoor, (unknown), Sara Balduzzi, Hendrik A. Marsman, Marnix H. Geukes Foppen, Cecile Grootscholten, Simone Dokter, A.G. den Hartog, Wieke H.M. Verbeek, Karlijn Woensdregt, (unknown), Steven J. Oosterling, Ton N. Schumacher, Koert F.D. Kuhlmann, Regina G. H. Beets‐Tan, John B.A.G. Haanen, Monique E. van Leerdam, José G. van den Berg, Myriam Chalabi	40
2	503O Neoadjuvant nivolumab (nivo) plus relatlimab (rela) in MMR-deficient colon cancer: Results of the NICHE-3 study 2024 ·Annals of Oncology ·(unknown), Y.L. Verschoor, (unknown), Sara Balduzzi, (unknown), Cecile Grootscholten, Simone Dokter, A.G. den Hartog, Jacobus W. A. Burger, Wieke H.M. Verbeek, (unknown), Eduard R. Hendriks, Steven J. Oosterling, R.G.H. Beets-Tan, (unknown), J.B.A.G. Haanen, Koert F.D. Kuhlmann, Monique E. van Leerdam, José G. van den Berg, Myriam Chalabi	1
3	LBA31 Neoadjuvant nivolumab plus relatlimab (anti-LAG3) in locally advanced MMR-deficient colon cancers: The NICHE-3 study 2023 ·Annals of Oncology ·Y.L. Verschoor, (unknown), Sara Balduzzi, (unknown), Steven J. Oosterling, (unknown), (unknown), (unknown), Simone Dokter, Regina G. H. Beets‐Tan, (unknown), Geerard L. Beets, Monique E. van Leerdam, J.B.A.G. Haanen, Myriam Chalabi	16
4	The effect of selective decontamination on the intestinal microbiota as measured with IS-pro: a taxonomic classification tool applicable for direct evaluation of intestinal microbiota in clinical routine 2022 ·European Journal of Clinical Microbiology & Infectious Diseases ·(unknown), G.S.A. Abis, Steven J. Oosterling, Marjolein van Egmond, Linda Poort, Hein B.A.C. Stockmann, H. Jaap Bonjer, Paul H. M. Savelkoul, Andries E. Budding	6
5	LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study breakdown → 2022 ·Annals of Oncology ·Myriam Chalabi, Y.L. Verschoor, (unknown), Karolina Sikorska, Geerard L. Beets, (unknown), (unknown), (unknown), (unknown), Hendrik A. Marsman, Eduard R. Hendriks, (unknown), (unknown), Steven J. Oosterling, Regina G. H. Beets‐Tan, Ton N. Schumacher, Monique E. van Leerdam, (unknown), J.B.A.G. Haanen	129
6	AbcApp: incidence of intra-abdominal ABsCesses following laparoscopic vs. open APPendectomy in complicated appendicitis 2022 ·Surgical Endoscopy ·(unknown), (unknown), (unknown), A. Rijbroek, Frank W. Bloemers, Steven J. Oosterling	10
7	Randomized clinical trial of selective decontamination of the digestive tract in elective colorectal cancer surgery (SELECT trial) 2019 ·British journal of surgery ·(unknown), G.S.A. Abis, Hein B.A.C. Stockmann, H. Jaap Bonjer, Nadine van Veenendaal, (unknown), Andries E. Budding, (unknown), Marjolein van Egmond, Steven J. Oosterling, (unknown), (unknown), (unknown), Jurriaan B. Tuynman, Christina M. J. E. Vandenbroucke‐Grauls, (unknown), Gerben J. van der Bij, N. de Korte, Yaïr I. Z. Acherman, Frank C. den Boer, D J A Sonneveld, Linda Poort	69
8	Structured training pathway and proctoring; multicenter results of the implementation of transanal total mesorectal excision (TaTME) in the Netherlands 2019 ·Surgical Endoscopy ·M. Veltcamp Helbach, Stefan van Oostendorp, T. W. A. Koedam, Jan Knol, Hein B.A.C. Stockmann, Steven J. Oosterling, (unknown), Eelco J. R. de Graaf, Pascal G. Doornebosch, Roel Hompes, H. Jaap Bonjer, Colin Sietses, Jurriaan B. Tuynman	46
9	Spillage of bacterial products during colon surgery increases the risk of liver metastases development in a rat colon carcinoma model. 2018 ·OncoImmunology ·(unknown), (unknown), Marijn Bögels, Rens Braster, Niels Heemskerk, Andries E. Budding, Stephan M. Pouw, Jack van Horssen, Marjolein Ankersmit, Jeroen Meijerink, Petrousjka van den Tol, Steven J. Oosterling, Jaap Bonjer, Nuray Gül, Marjolein van Egmond	7
10	Influence of Conversion and Anastomotic Leakage on Survival in Rectal Cancer Surgery; Retrospective Cross-sectional Study 2018 ·Journal of Gastrointestinal Surgery ·Edgar J.B. Furnée, Tjeerd S. Aukema, Steven J. Oosterling, Wernard A. A. Borstlap, Willem A. Bemelman, Pieter J. Tanis	25
11	A prospective study on an innovative online forum for peer reviewing of surgical science 2017 ·PLoS ONE ·Martin Almquist, Regula S. von Allmen, Daniel Carradice, Steven J. Oosterling, (unknown), Bas P. L. Wijnhoven	4
12	Training residents in laparoscopic colorectal surgery: is supervised surgery safe? 2016 ·Surgical Endoscopy ·(unknown), R. Silvis, (unknown), Steven J. Oosterling, Herman Rijna, Hein B.A.C. Stockmann	16
13	Peri-Operative Bowel Perforation in Early Stage Colon Cancer is Associated with an Adverse Oncological Outcome 2012 ·Journal of Gastrointestinal Surgery ·Eric J.T. Belt, Hein B.A.C. Stockmann, G.S.A. Abis, (unknown), Elly S.M. de Lange–de Klerk, Marjolein van Egmond, Gerrit A. Meijer, Steven J. Oosterling	17
14	Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy 2010 ·Journal of Hepatology ·Gerben J. van der Bij, Marijn Bögels, Marielle A. Otten, Steven J. Oosterling, Peter J.K. Kuppen, Sybren Meijer, Robert H.J. Beelen, Marjolein van Egmond	43
15	The Perioperative Period is an Underutilized Window of Therapeutic Opportunity in Patients With Colorectal Cancer 2009 ·Annals of Surgery ·Gerben J. van der Bij, Steven J. Oosterling, Robert H.J. Beelen, Sybren Meijer, John Calvin Coffey, Marjolein van Egmond	161
16	Tumor infiltrating macrophages reduce development of peritoneal colorectal carcinoma metastases 2008 ·Cancer Letters ·Gerben J. van der Bij, Marijn Bögels, Steven J. Oosterling, Jeffrey Kroon, (unknown), Helga E. de Vries, Sybren Meijer, Robert H.J. Beelen, Marjolein van Egmond	33
17	Blocking α2 integrins on rat CC531s colon carcinoma cells prevents operation-induced augmentation of liver metastases outgrowth 2007 ·Hepatology ·Gerben J. van der Bij, Steven J. Oosterling, Marijn Bögels, (unknown), Donna Fluitsma, Robert H.J. Beelen, Sybren Meijer, Marjolein van Egmond	43
18	The Role of Macrophages in Tumor Development 2005 ·Analytical Cellular Pathology ·Gerben J. van der Bij, Steven J. Oosterling, Sybren Meijer, Robert H.J. Beelen, Marjolein van Egmond	29
19	Surgery promotes implantation of disseminated tumor cells, but does not increase growth of tumor cell clusters 2005 ·Journal of Surgical Oncology ·Sander Ten Raa, Steven J. Oosterling, Niels P. van der Kaaij, M.P. van den Tol, R.H.J. Beelen, S. Meijer, Casper H.J. van Eijck, Joost R.M. van der Sijp, Marjolein van Egmond, Johannes Jeekel	52
20	Macrophages direct tumour histology and clinical outcome in a colon cancer model 2005 ·The Journal of Pathology ·Steven J. Oosterling, Gerben J. van der Bij, Gerrit A. Meijer, Cornelis W. Tuk, E. van Garderen, Nico van Rooijen, Sybren Meijer, (unknown), Robert H.J. Beelen, Marjolein van Egmond	101

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact